OUTCOMES OF 5-ALA FLIORESCECE-GUIDED SURGERY FOR HIGH GRADE G

High grade gliomas (HGG) are the most aggressive primary brain tumors. The extent of resection (EOR) is proved to be an important prognostic factor in patients with HGG. There are no yet published studies on the use of fluorescent-guided resection using 5-aminolevulinic acid (5-ALA) in HGG surgery, based on the comparison of neuroimaging characteristics, intraoperative parameters and clinical outcomes. The purpose of this study was to analyze the results of 5-ALA fluorescent-guided resection in patients with HGG by comparing neuroimaging characteristics, intraoperative parameters and clinical outcomes. Material and methods. The study included 48 patients (30 men and 18 women) aged 35 to 76 years (mean age 47.3 ± 8.4 years) with newly diagnosed HGG. The patients underwent fluorescent-guided surgery that permitted the intraoperative visualization of malignant glioma tissue and supported the neurosurgeon with real-time guidance for differentiating tumor from normal brain. The Karnofsky performance status (KPS) was assessed. Results. The maximum EOR (90–98 %) was achieved in 40 (83.3 %) patients with newly diagnosed HGG. The maximum EOR was performed in 28 (58.3 %) patients with glioblastomas and in 12 (25 %) patients with grade III gliomas (p=0.408) In addition, the maximum EOR was achieved by microneurosurgical removal of 9 (18.75 %) HGGs having a volume of ≥9 cm3 and 21 (43.75 %) of HGGs with a volume<9 cm3 (p=0.029). The tumor boundaries detected by neuronavigation differed by fluorescence data in 28 (58.3 %) patients The divergence between neuronavigation and 5-ALA fluorescence was reported in 19 (39.5 %) patients with glioblastomas and in 3 (6.25 %) patients with grade III gliomas (p=0.014); and in 9 (39.5 %) and in 14 (29.1 %) patients affected with larger (≥9 cm3 ) and smaller (<9 cm3 ) tumor, respectively (p=0.677). Overall, 36 (75 %) patients experienced an improvement in their KPS score, 9 (18.75 %) remained stable, and 3 (6.25 %) declined. Conclusion. The use of 5-ALA fluorescence in surgery for HGG makes it possible to achieve the gross total resection in most cases. The localization of HGGs and their size are the most important factors in achieving maximum EOR. Key words: high grade gliomas, fluorescent navigation, 5-aminolevulinic acid, extent of tumor resection><9cm3 ) tumor, respectively (p=0.677). Overall, 36 (75 %) patients experienced an improvement in their KPS score, 9 (18.75 %) remained stable, and 3 (6.25 %) declined. Conclusion. The use of 5-ALA fluorescence in surgery for HGG makes it possible to achieve the gross total resection in most cases. The localization of HGGs and their size are the most important factors in achieving maximum EOR.

1. Byvaltsev V.A., Stepanov I.A., Yarullina A.I., Belykh E.G. Molecular aspects of angiogenesis in gliobalstoma. Problems in Oncology. 2017; 63 (1): 19–27. [in Russian]

2. Belykh E., Martirosyan N.L., Yagmurlu K., Miller E.J., Eschbacher J.M., Izadyyazdanabadi M., Bardonova L.A., Byvaltsev V.A., Nakaji P., Preul M.C. Intraoperative Fluorescence Imaging for Personal-ized Brain Tumor Resection: Current State and Future Directions. Front Surg. 2016 Oct 17; 3: 55

3. Byvaltsev V.A., Stepanov I.A. Intraoperative fluorescence-guided resection of high-grade glioblastoma using 5-aminolevulinic acid: a meta-analysis. Siberian journal of oncology. 2017; 16 (4): 54–64. [In Russian]

4. Keles G.E., Lamborn K.R., Chang S.M., Prados M.D., Berger M.S. Volume of residual disease as a predictor of outcome in adult patients with recurrent supratentorial glioblastomas multiforme who are undergoing chemotherapy. J Neurosurg. 2004; 100 (1): 41–46. doi: 10.3171/jns.2004.100.1.0041.

5. Chaichana K.L., Jusue-Torres I., Navarro-Ramirez R., Raza S.M., Pascual-Gallego M., Ibrahim A., Hernandez-Hermann M., Gomez L., Ye X., Weingart J.D., Olivi A., Blakeley J., Gallia G.L., Lim M., Brem H., Quinones-Hinojosa A. Establishing percent resection and residual volume thresholds affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro Oncol. 2014 Jan; 16 (1): 113–22. doi: 10.1093/neuonc/not137.

6. Lacroix M., Abi-Said D., Fourney D.R., Gokaslan Z.L., Shi W., DeMonte F., Lang F.F., McCutcheon I.E., Hassenbusch S.J., Holland E., Hess K., Michael C., Miller D., Sawaya R. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001; 95 (2): 190–198. doi: 10.3171/ jns.2001.95.2.0190.

7. Sanai N., Polley M., McDermott M., Parsa A.T., Berger M.S. An extent of resection threshold for newly diagnosed glioblastomas: clinical article. J Neurosurg. 2011 Jul; 115 (1): 3–8. doi: 10.3171/2011.2.JNS10998.

8. Idoate M.A., Díez Valle R., Echeveste J., Tejada S. Pathological characterization of the glioblastoma border as shown during surgery using 5-aminolevulinic acid-induced fluorescence. Neuropathology. 2011 Dec; 31 (6): 575–82. doi: 10.1111/j.1440-1789.2011.01202.x.

9. Teixidor P., Arráez M.Á., Villalba G., Garcia R., Tardáguila M., González J.J., Rimbau J., Vidal X., Montané E. Safety and Efficacy of 5-Aminolevulinic Acid for High Grade Glioma in Usual Clinical Practice: A Prospective Cohort Study. PLoS One. 2016 Feb 17; 11 (2): e0149244. doi: 10.1371/journal.pone.0149244.

10. Roberts D.W., Valdés P.A., Harris B.T., Hartov A., Fan X., Ji S., Leblond F., Tosteson T.D., Wilson B.C., Paulsen K.D. Glioblastoma Multiforme Treatment with Clinical Trials for Surgical Resection (Aminolevulinic Acid). Neurosurg Clin N Am. 2012 Jul; 23 (3): 371–7. doi: 10.1016/j.nec.2012.04.001.

11. Piccirillo S.G., Dietz S., Madhu B., Griffiths J., Price S.J., Col-lins V.P., Watts C. Fluorescence-guided surgical sampling of glioblastoma identifies phenotypically distinct tumour-initiating cell populations in the tumour mass and margin. Br J Cancer. 2012 Jul 24; 107 (3): 462–8. doi: 10.1038/bjc.2012.271

12. Vogelbaum M.A., Jost S., Aghi M.K., Heimberger A.B., Samp-son J.H., Wen P.Y., Macdonald D.R., Van den Bent M.J., Chang S.M. Application of novel response/progression measures for surgically delivered therapies for gliomas; Response Assessment in Neuro-Oncology (RANO) working group. Neurosurg. 2012 Jan; 70 (1): 234–43. doi: 10.1227/NEU.0b013e318223f5a7.

13. Schucht P., Beck J., Abu-Isa J., Andereggen L., Murek M., Seidel K., Stieglitz L., Raabe A. Gross total resection rates in contemporary glioblastoma surgery: results of an institutional protocol combining 5-ALA intraoperative fluorescence imaging and brain mapping. Neurosurg. 2012 Nov; 71(5): 927–35; discussion 935–6. doi: 10.1227/ NEU.0b013e31826d1e6b.

14. Gaytan A.S., Krivoshapkin A.L., Kanygin V.V., Valentik A.V., Karaskov A.M. Results of brain glioblastoma resection using combined fluorescent navigation. Blood Circulation Pathology and Cardiosurgery. 2014; 18 (2): 37–41. [in Russian]

15. Stummer W., Pichlmeier U., Meinel T., Wiestler O.D., Zanella F., Reulen H.J.; ALA-Glioma Study Group. ALA-Glioma Study Group. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: A randomised controlled multicentre phase III trial. Lancet Oncol. 2008; 7: 392–401.

16. Feigl G.C., Ritz R., Moraes M., Klein J., Ramina K., Gharabaghi A., Krischek B., Danz S., Bornemann A., Liebsch M., Tatagiba M.S. Resection of malignant brain tumors in eloquent cortical areas: a new multimodal approach combining 5-aminolevulinic acid and intra-operative monitoring. J Neurosurg. 2010 Aug; 113 (2): 352–7. doi: 10.3171/2009.10.JNS09447.

17. Della Puppa A., De Pellegrin S., d’Avella E., Gioffrè G., Rossetto M., Gerardi A., Lombardi G., Manara R., Munari M., Saladini M., Scienza R. 5-aminolevulinic acid (5-ALA) fluorescence guided surgery of high-grade gliomas in eloquent areas assisted by functional mapping. Our experience and review of the literature. Acta Neurochir (Wien). 2013 Jun; 155(6): 965–72; discussion 972. doi: 10.1007/s00701-013-1660-x.

18. Díez Valle R., Slof J., Galván J., Arza C., Romariz C., Vidal C.; VISIONA study researchers. Observational, retrospective study of the effectiveness of 5-aminolevulinic acid in malignant glioma surgery in Spain (The VISIONA study). Neurologia. 2014 Apr; 29 (3): 131–8. doi: 10.1016/j.nrl.2013.05.004.

19. De Witt Hamer P.C., Robles S.G., Zwinderman A.H., Duffau H., Berger M.S. Impact of intraoperative stimulation brain mapping on glioma surgery outcome: a meta-analysis. J Clin Oncol. 2012 Jul 10; 30 (20): 2559–65. doi: 10.1200/JCO.2011.38.4818.

20. Chang E.F., Clark A., Smith J.S., Polley M.Y., Chang S.M., Barbaro N.M., Parsa A.T., McDermott M.W., Berger M.S. Functional mapping-guided resection of low-grade gliomas in eloquent areas of the brain: improvement of long-term survival. J Neurosurg. 2011 Mar; 114 (3): 566–73. doi: 10.3171/2010.6.JNS091246.

21. Hervey-Jumper S.L., Li J., Lau D., Molinaro A.M., Perry D.W., Meng L., Berger M.S. Awake craniotomy to maximize: methods and technical nuances over a 27-year period. J Neurosurg. 2015; 123: 325–339.

22. Byvaltsev V.A., Yarullina A.I., Stepanov I.A., Shashkov K.V. Glioblastoma resection using fluorescence navigation. Siberian Medical Journal (Irkutsk). 2015; 138 (7): 128–132. [in Russian]